The latter was assessed in both aphasic (i.e., PPA) and amnestic (i.e., DAT) clinical phenotypes to determine whether 3R/4R tau pathology of AD in the DG varies with the absence or presence of memory deficits at onset. The gene discussed is MAPT; the disease is primary progressive aphasia.